Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance.

The orally administered tubulin-binding agent 1069C85 was developed with the hope of overcoming the multidrug resistance associated with existing anti-tubulin agents, such as the vinca alkaloids. A phase I study was performed using a single oral dose every 3 weeks, administered as a suspension recon...

Descripción completa

Detalles Bibliográficos
Autores principales: Judson, I., Briasoulis, E., Raynaud, F., Hanwell, J., Berry, C., Lacey, H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063322/
https://www.ncbi.nlm.nih.gov/pubmed/9052420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063322/
https://www.ncbi.nlm.nih.gov/pubmed/9052420

Ejemplares similares